Home page4507 • TYO
add
Shionogi & Co.
Chiusura precedente
2059,00 ¥
Intervallo giornaliero
2062,50 ¥ - 2109,50 ¥
Intervallo annuale
1944,66 ¥ - 2712,33 ¥
Cap di mercato
1,86Â Bln JPY
Volume medio
2,61Â Mln
Rapporto P/E
11,59
Dividendo/Prezzo
2,71%
Borsa valori principale
TYO
Notizie del mercato finanziario
GS
1,12%
0,35%
Dati finanziari
Conto economico
Entrate
Utile netto
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Entrate | 116,38Â Mld | -4,00% |
Spese di gestione | 52,93Â Mld | -3,66% |
Utile netto | 52,50Â Mld | 9,30% |
Margine di profitto netto | 45,11 | 13,86% |
Utili per azione | — | — |
EBITDA | 53,13Â Mld | -5,14% |
Aliquota fiscale effettiva | 8,28% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 303,40Â Mld | 20,22% |
Totale attivo | 1,46Â Bln | 3,34% |
Totale passivo | 145,93Â Mld | -18,09% |
Patrimonio netto totale | 1,31 Bln | — |
Azioni in circolazione | 850,69 Mln | — |
Prezzo/valore contabile | 1,23 | — |
Redditività dell'attivo | 8,22% | — |
Rendimento sul capitale | 9,10% | — |
Flusso di cassa
Flusso di cassa netto
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 52,50Â Mld | 9,30% |
Liquidità di esercizio | 45,30 Mld | 220,14% |
Contanti da investimenti | -17,63Â Mld | 47,30% |
Contanti da finanziamenti | -1,11Â Mld | 94,50% |
Flusso di cassa netto | 21,45Â Mld | 158,43% |
Flusso di cassa libero | 8,02Â Mld | 135,46% |
Informazioni
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Fondazione
1878
Sito web
Dipendenti
4.959